<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34370958</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1563-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The International journal of neuroscience</Title><ISOAbbreviation>Int J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Posterior reversible encephalopathy syndrome during convalescence from COVID-19.</ArticleTitle><Pagination><StartPage>672</StartPage><EndPage>675</EndPage><MedlinePgn>672-675</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/00207454.2021.1966629</ELocationID><Abstract><AbstractText><b>Background and aim:</b> With an ever-increasing population of patients recovering form severe coronavirus disease 2019 (COVID-19), recognizing long-standing and delayed neurologic manifestations is crucial. Here, we present a patient developing posterior reversible encephalopathy syndrome (PRES) in the convalescence form severe coronavirus disease 2019 (COVID-19).<b>Case presentation:</b> A 61-year-old woman with severe (COVID-19) confirmed by nasopharyngeal real-time reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) required invasive mechanical ventilation 24-hours after admission. During her intensive care unit stay, she developed transient acute kidney injury and septic shock. She was extubated after 22&#x2009;days. On day 25, she developed generalized tonic-clonic seizures. Magnetic resonance imaging (MRI) of the brain showed bilateral subcortical lesions on the parietal and occipital lobes and multiple micro-and macro-bleeds, consistent with PRES. At this point, RT-PCR for SARS-CoV-2 in a respiratory specimen and cerebrospinal fluid was negative. She was discharged home 35&#x2009;days after admission on oral levetiracetam. Control MRI five months after discharge showed bilateral focal gliosis. On follow-up, she remains seizure-free on levetiracetam.<b>Conclusions:</b> PRES has been observed before as a neurological manifestation of acute COVID-19; to our knowledge, this is the first PRES case occurring in a hospitalized patient already recovered from COVID-19. A persistent proinflammatory/prothrombotic state triggered by SARS-CoV-2 infection may lead to long-standing endothelial dysfunction, resulting in delayed PRES in patients recovering from COVID-19. With a rapid and exponential increase in survivors of acute COVID-19, clinicians should be aware of delayed (post-acute) neurological damage, including PRES.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michel-Ch&#xe1;vez</LastName><ForeName>Anaclara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Grimshaw</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5287-1068</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ch&#xe1;vez-Mart&#xed;nez</LastName><ForeName>Oswaldo Alan</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cant&#xfa;-Brito</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-S&#xe1;nchez</LastName><ForeName>Griselda Teresa</ForeName><Initials>GT</Initials><Identifier Source="ORCID">0000-0002-5835-1888</Identifier><AffiliationInfo><Affiliation>Department of Neuroradiology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores-Silva</LastName><ForeName>Fernando Daniel</ForeName><Initials>FD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merayo-Chalico</LastName><ForeName>Francisco Javier</ForeName><Initials>FJ</Initials><Identifier Source="ORCID">0000-0002-5870-0523</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Carrillo</LastName><ForeName>Francisco Manuel</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Neurologic Center, Centro M&#xe9;dico ABC, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrera-Vargas</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vald&#xe9;s-Ferrer</LastName><ForeName>Sergio Iv&#xe1;n</ForeName><Initials>SI</Initials><Identifier Source="ORCID">0000-0002-4863-6484</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Feinstein Institute for Medical Research, Center for Biomedical Science, Manhasset, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Neurosci</MedlineTA><NlmUniqueID>0270707</NlmUniqueID><ISSNLinking>0020-7454</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>44YRR34555</RegistryNumber><NameOfSubstance UI="D000077287">Levetiracetam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054038" MajorTopicYN="Y">Posterior Leukoencephalopathy Syndrome</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003289" MajorTopicYN="N">Convalescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077287" MajorTopicYN="N">Levetiracetam</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PRES</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cerebrovascular dysfunction</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">seizures</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>9</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34370958</ArticleId><ArticleId IdType="doi">10.1080/00207454.2021.1966629</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>